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Background: Cellular senescence represents a tumor suppressive response to a variety of aberrant and oncogenic
insults. We have previously described a transgenic mouse model of Cyclin D1-driven senescence in pineal cells that
opposes tumor progression. We now attempted to define the molecular mechanisms leading to p53 activation in
this model, and to identify effectors of Cyclin D1-induced senescence.
Results: Senescence evolved over a period of weeks, with initial hyperproliferation followed by cell cycle arrest due
to ROS production leading to activation of a DNA damage response and the p53 pathway. Interestingly, cell cycle
exit was associated with repression of the Cyclin-dependent kinase Cdk2. This was followed days later by formation
of heterochromatin foci correlating with RB protein hypophosphorylation. In the absence of the Cdk4-inhibitor
p18Ink4c, cell cycle exit was delayed but most cells eventually showed a senescent phenotype. However, tumors
later arose from this premalignant, largely senescent lesion. We found that the p53 pathway was intact in tumors
arising in a p18Ink4c-/- background, indicating that the two genes represent distinct tumor suppressor pathways.
Upon tumor progression, both p18Ink4c-/- and p53-/- tumors showed increased Cdk2 expression. Inhibition of Cdk2
in cultured pre-tumorigenic and tumor cells of both backgrounds resulted in decreased proliferation and evidence
of senescence.
Conclusion: Our findings indicate that the p53 and the RB pathways play temporally distinct roles in senescence
induction in Cyclin D1-expressing cells, and that Cdk2 inhibition plays a role in tumor suppression, and may be a
useful therapeutic target.
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Cellular senescence is a well-established tumor suppressor
mechanism, activated in response to oncogenic signals,
DNA damage, and telomere attrition among other pro-
tumorigenic insults (reviewed in [1,2]). Mechanistic insight
into oncogene-induced senescence has emerged over the
past few years. While it is clear that both the p53 and the
Rb tumor suppressors are involved [3-6], their relative im-
portance seems to vary depending on the activating insult* Correspondence: rs88@aub.edu.lb
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reproduction in any medium, provided the orand cellular context [3,7-10]. Understanding the relative
contributions of p53 and Rb to the induction and mainten-
ance of senescence may have important implications, espe-
cially with development of targeted therapeutic agents.
Cyclin-dependent kinase 2 (Cdk2) was recently impli-
cated in the senescence process, as Cdk2 loss was found
to enhance senescence in Myc-induced tumors [11]. In
addition, it was shown that Cdk2-dependent phosphoryl-
ation of Myc was necessary to bypass Ras-induced senes-
cence [12]. This suggests that Cdk2 may act in
senescence independently of its role in RB phosphoryl-
ation and cell cycle exit.
Here, we used a transgenic mouse model of premalig-
nant Cyclin D1-driven pineal gland hyperplasia, to define
the molecular mechanisms leading to p53 activation intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Zalzali et al. Molecular Cancer 2012, 11:28 Page 2 of 12
http://www.molecular-cancer.com/content/11/1/28response to Cyclin D1, and to identify effectors of Cyclin
D1-induced senescence. The results shed light on the
pattern of evolution of the senescence response in a pre-
malignant lesion in vivo, and the differences in the con-
tribution of the two major tumor suppressor pathways,
p53 and RB. In addition, our findings suggest that Cdk2
inhibition may be a useful therapeutic approach, irre-
spective of the underlying genetic insult that led to sen-
escence evasion.
Results
Cyclin D1-induced senescence in vivo occurs over a time
frame of several weeks: We used the Irbp-Cyclin D1
mouse in which the expression of Cyclin D1 in the pineal
gland causes excessive proliferation that is limited by
senescence. The net result is a hyperplastic but senescent
pineal gland that does not progress into an invasive
tumor unless either p53 or the Cdk4-inhibitor p18Ink4c is
lost [13]. We examined the temporal evolution of senes-
cence and the contribution of the p53 and Rb tumor
suppressor pathways to cell cycle exit in vivo.
Histological studies of Cyclin D1-expressing pineal
glands at various ages (post-natal day (P)10, P24, P35,
and P49) showed that enhanced proliferation, measured
by Ki67 immunostaining, was apparent at P10 but after
this point it decreased such that essentially all cells had
exited the cell cycle by P35 [Figure 1A, left panel,
Quantitation in Figure 1B]. Cessation of proliferation
preceded the formation of senescence-associated hetero-
chromatin foci (SAHF); in fact, there was anFigure 1 Cyclin D1-induced senescence occurs over several weeks. A)
(left); immunoflourescence staining for Histone 3 trimethylated at Lysine 9
corresponding DAPI staining (right). B) Quantitation of Ki67-positive cells as
Dec1, DcR2, and p15Ink4b, in Irbp-Cyclin D1 pineal glands at the indicatedunexpectedly long, two-week delay from P35 to P49 be-
fore SAHF were apparent [Figure 1A, middle and right
panels]. Because SAHF have been observed in only a few
mouse models of senescence [14-16], but not in other
murine cells like MEFs [17], and because constitutive
centromeric heterochromatin may show intense DAPI
staining mimicking SAHF in normal murine cells
[18,19], we verified that these foci were indeed only seen
in Cyclin D1-expressing cells and not the wild-type
counterparts at P49 [Additional file 1: Figure S1A]. We
could not detect positive staining for senescence-asso-
ciated beta galactosidase (SABG), another marker of sen-
escence [20]. However, we believe this must be a
technical issue (detecting the enzyme activity necessi-
tates freshly frozen tissue), because when the Cyclin D1-
expressing pineal cells were grown in vitro, they showed
features of senescence that included positive staining for
SABG [see below, and Additional file 1: Figure S1B]. In
addition, we evaluated the pineal cells for other known
markers of senescence, such as Dec1, DcR2, and
p15Ink4b [21]. We found that, concomitant with cell
cycle exit and SAHF formation, all three markers of sen-
escence were increased at P49 [Figure 1C]. We conclude
that Cyclin D1-induced senescence in the pineal cells
occurs by P49, and that cell cycle exit in this setting
occurs many days prior to expression of bona fide mar-
kers of senescence.
p53 activation occurs prior to cell cycle exit, and is
mediated by a ROS-induced DNA damage response: To
identify when p53 was engaged in tumor suppression, weKi67 staining of Irbp-Cyclin D1 pineal sections at the indicated ages
(H3K9me3) in pineal sections at the indicated ages (middle), with
percent of total pineal cells at indicated ages. C) Immunostaining for
ages.
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ent postnatal ages. We found that at P10, p53 protein ex-
pression was increased, as was its phosphorylation at
Ser15/20 (a site phosphorylated by the DNA damage re-
sponse) [Figure 2A]. The p53 target, p21Cip1, was also
induced at that time-point [Figure 2A]. However, p53 ac-
tivation did not persist once the cells had exited the cell
cycle nor was it detectable at P49 when the cells dis-
played SAHF [Figure 2A].
We hypothesized that Cyclin D1 expression may be
inducing p53 through activation of the DNA damage
response (DDR), as reported for Ras-induced senes-
cence (reviewed in [22]). Indeed, we found nuclear ac-
cumulation of phosphorylated histone H2AX (pH2AX)
at P10, concomitant with p53 activation [Figure 2B,
2C]. In addition, Chk1 was phosphorylated concomi-
tantly with phosphorylation of p53, further indicating
that the DDR pathway was active in the transgenic
pineal gland at this time, but not at later time-points
[Figure 2D]. These findings reveal that deregulated
Cyclin D1 enhances the DDR pathway and activates
p53 while cells are proliferating, but ongoing DDRFigure 2 Cyclin D1-induced cell cycle exit is associated with early p53
the indicated proteins in Irbp-Cyclin D1 pineal glands at the indicated ages.
immunostaining for γH2AX in Irbp-Cyclin D1 (D1) and wild-type (WT) pineal
-positive pinealocytes in wild-type (WT) and Irbp-Cyclin D1 (D1) pineal sectio
to six separate mice; bars, SD. D) Western blotting for the indicated protein
indicated ages. HA: HA epitope on the Cyclin D1 transgene. Hsc70 is a loadand active p53 are not needed after cells have under-
gone senescence.
We next assessed whether reactive oxygen species
(ROS) may be contributing to Cyclin D1-induced senes-
cence in pineal cells, based on their role in Ras-induced
senescence in cultured fibroblasts [23-25]. Using DCF-
DA assay in explanted pineal cells, we found that ROS
were indeed induced in response to Cyclin D1 expres-
sion, but not in wild-type pineal cells grown in the same
conditions [Figure 3A]. We investigated whether ROS
were responsible for activation of the DNA damage re-
sponse in this setting. Indeed, Cyclin D1-induced ROS
resulted in DNA damage foci marked by pH2AX, as well
as the ROS-induced incorporation of oxidized dNTP, 8-
Oxo-dGTP, into DNA [Additional file 1: Figure S1D]. It
also led to phosphorylation of Chk1, a component of the
DNA damage response pathway [Figure 3B, left panel],
and to increased expression of two p53 pathway effector
proteins, 14-3-3 and p21 [Figure 3B, middle and right
panels]. Treating cells with the ROS scavenger N-Acetyl
Cysteine (NAC) resulted in abrogation of DNA damage
[Additional file 1: Figure S1D], abrogation of DDRactivation and a DNA damage response. A) Western blotting for
HA: HA epitope on the Cyclin D1 transgene. B) Representative
sections at the indicated ages. C) Quantitative analysis of γH2AX
ns at the indicated ages. Columns: mean of measurements from three
s in wild-type (WT) and Irbp-Cyclin D1 (D1) pineal glands at the
ing control.
Figure 3 Cyclin D1 expression leads to ROS accumulation, which results in a DNA damage response and senescence induction. A)
DCFDA assay in cultured pineal cells that are either wild-type (WT) or express Cyclin D1 (Cyclin D1). PC = phase contrast; OL = overlay. B)
Immunofluorescence staining for the respective proteins in cultured Cyclin D1-expressing pineal cells (top panel), which have been treated with
N-Acetyl Cysteine (NAC) or vehicle. The middle panel shows the respective DAPI-stained nuclei, and the lower panel shows the overlay (OL). C)
Staining for senescence-associated beta galactosidase (SABG) in explanted Cyclin D1-expressing cells that have been treated with either NAC or
vehicle, as indicated. D) Representative immunofluorescence staining for 4-hydroxynonenal (4HNE) in 10-day old Irbp-Cyclin D1 (D1) and wild-type
(WT) pineal sections, as indicated. E) Representative immunostaining for the mitochondrial superoxide dismutase MnSOD in wild-type (WT) and
Irbp-Cyclin D1 (D1) pineal sections, as indicated.
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[Figure 3B], as well as evasion of senescence [Figure 3C].
By staining for 4-hydroxy-nonenal (HNE), a marker of
lipid oxidation, we found evidence of oxidative stress in
pineal sections of Irbp-Cyclin D1 mice, but not wild-type
mice [Figure 3D], and there was also increased expres-
sion of the mitochondrial superoxide dismutase protein
MnSOD [Figure 3E], which is induced by ROS stress
in vivo [26]. Thus, from the above in vitro and in vivo
evidence, we conclude that Cyclin D1 expression results
in accumulation of ROS, which in turn leads to activa-
tion of the DDR and the p53 pathway, resulting in induc-
tion of senescence.
RB pathway activation occurs after cell cycle exit and
is associated with SAHF: To evaluate when the Rbpathway was engaged, we used western blotting to inves-
tigate the Cdk-dependent phosphorylation of Rb in pin-
eal cell lysates. We investigated the status of Rb
phosphorylation at Cdk4-dependent sites such as Ser790,
and at Cdk2-dependent sites such as Ser612 [Figure 4A].
We found that Rb was phosphorylated at Cdk2-
dependent sites (Ser612) at P10, when cells were prolifer-
ating, but decreased after cells exited the cell cycle by
P24 [Figure 4A]. In contrast, Rb was phosphorylated at
Cdk4-dependent sites (Ser790) from P10 through P35,
even though most cells had ceased to proliferate by P24
[Figure 4A]. Rb phosphorylation at Cdk4-dependent sites
was reversed at P49 as SAHF formed [Figure 4A].
To understand the mechanism of Rb activation, we inves-
tigated the expression of the Cdk-inhibitors p16Ink4a,
Figure 4 p18Ink4c loss delays Cyclin D1-induced senescence. A) and B) Western blotting for the indicated proteins in wild-type (WT) and Irbp-
Cyclin D1 (D1) pineal glands at the indicated ages. Hsc70 is a loading control. C) Quantitative analysis of Ki67-positive pinealocytes in Irbp-Cyclin
D1, p53-/- (D1p53n), and Irbp-Cyclin D1, p18Ink4c-/- (D1p18n) mice of the indicated ages, compared to p53-/- and p18Ink4c-/- controls, respectively.
Columns: mean of measurements from three to six separate mice; bars, SD. D) Western blotting for the indicated proteins in Irbp-Cyclin D1 (D1)
and Irbp-Cyclin D1, p18Ink4c-/- (D1p18n) pineal glands at the indicated ages. HA: epitope on the Cyclin D1 transgene.
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increased expression of p18Ink4c at all time points
[Figure 3B], an increase in p15Ink4b expression at P49 [see
Figure 1D], but no changes in expression of p16Ink4a and
p27Kip1 (not shown). We also evaluated the expression of
Cdk4 and Cdk2, especially since Cdk2 inhibition was re-
cently found to be important for Myc-induced senescence
[11]. We observed a modest decrease in Cdk4 expression
from P10 through P49 [Figure 3B], but interestingly we
found that Cdk2 expression was markedly reduced from
P10 to P24 [Figure 3B], coincident with the timing of cell
proliferation arrest and loss of Rb phosphorylation at
Cdk2-specific sites. We conclude that Cdk2 repression
correlates most closely with the initial proliferation arrest;
and that diminished Cdk4-dependent Rb phosphorylation
occurs at a later time-point and correlates with formation
of SAHF.
p18Ink4c loss delays p53-dependent cell cycle exit: Be-
cause of the observed increase in expression of p18Ink4c,
we used a genetic approach to evaluate its role in Cyclin
D1-induced senescence. In contrast to what occurs with-
out p53 – where cell proliferation only slightly decreases
from P10 to P35 and then increases as invasive tumor
progresses [Figure 4C, top panel; and [13]], proliferation
decreased from P10 through P49 without p18Ink4c[Figure 4C, bottom panel], but exceeded that in the Irbp-
Cyclin D1 cells [Figure 4C, bottom panel, compare with
Figure 1B].
Notably, p53 activation measured by phosphorylation
at Ser15/20, and expression of the p53-target p21Cip1,
persisted until P24 in Irbp-Cyclin D1, p18Ink4c -/- cells
[Figure 4D], correlating with the prolonged cellular pro-
liferation. Further, Cdk2 expression persisted until P24 in
Irbp-Cyclin D1, p18Ink4c -/- cells [Figure 4D]. These
findings indicate that p18Ink4c loss delayed but did not
prevent p53-dependent events leading to cell cycle exit.
Interestingly, loss of Cdk4-dependent Rb phosphoryl-
ation still occurred in the absence of p18Ink4c, again cor-
relating with the appearance of SAHF [Figure 4D]. In
fact, the majority of Irbp-Cyclin D1, p18Ink4c -/- cells
displayed SAHF by P49 [Additional file 2: Figure S2A],
whereas SAHF never formed in Irbp-Cyclin D1, p53 -/-
cells [13]. In addition to SAHF, the senescence markers
Dec1 and DcR2 were also expressed in Irbp-Cyclin D1,
p18Ink4c -/- cells at P49 [Additional file 1: Figure S2B].
Findings were similar in vitro using pineal cells explanted
from P10 animals and cultivated for 10-20 days:
Explanted Irbp-Cyclin D1 cells showed evidence of sen-
escence, including loss of proliferation (measured by
BrdU incorporation), and positive staining for SABG, by
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while the Irbp-Cyclin D1, p53 -/- cells continued to pro-
liferate and did not senesce [Additional file 1: Figure
S1B, bottom]. In contrast, the Irbp-Cyclin D1, p18Ink4c
-/- cells did show evidence of senescence, but it was
delayed until close to 20 days in culture [Additional file
2: Figure S2C]. We conclude that p18Ink4c slowed prolif-
eration but was not essential for most Cyclin D1 expres-
sing cells to cease proliferating and become senescent.
p53 and p18Ink4c act independently in suppressing
Cyclin D1-driven tumors: The persistence of a small
number of proliferating cells by P49, in Irbp-Cyclin D1,
p18Ink4c -/- mice, was important because it led to pineo-
blastoma by 7-10 months of age in all mice examined
(n= 15). Examining mice at 3-5 months of age, we
observed an obvious border between the malignant and
pre-malignant parts of the pineal gland [Figure 5A, left];
this border disappeared as the tumor infiltrated theFigure 5 p18Ink4c loss promotes emergence of tumor from a premali
Cyclin D1, p18Ink4c-/- mice at the indicated ages, with Ki67 immunostaining
Immunoflourescence for H3K9me3 and corresponding DAPI staining of Irbp
the emerging tumor; dashed line demarcates tumor from the senescent pi
H3K9me3). C) Dual immunoflourescence for BrdU (green) and H3K9me3 (re
cells with H3K9me3 foci, white arrows cells positive for BrdU. D) Western b
Cyclin D1, p53-/- (D1p53n) and Irbp-Cyclin D1, p18Ink4c-/- (D1p18n) mice, co
Cyclin D1 transgene. E) Representative western blot for the indicated prote
D1, p18Ink4c -/- (D1p18nT) mice, before and after treatment with ionizing r
indicated proteins in Irbp-Cyclin D1, p53 -/- (D1p53null) pineal lysates at thewhole pineal gland [Figure 5A, right], and SAHF were
lost in the emerging Irbp-Cyclin D1, p18Ink4c -/- tumor
[Figure 5B]. Dual immunostaining for BrdU and SAHF
clearly demonstrated that proliferating pinealocytes were
distinct from those that displayed SAHF [Figure 5C].
We considered whether the prolonged proliferation in
the absence of p18Ink4c might have derailed a p53-
dependent arrest in the malignant tumors. Western blot-
ting showed that Irbp-Cyclin D1, p18Ink4c -/- tumors
still expressed the p53 protein [Figure 5D], and sequen-
cing of p53 exons 5-8 did not reveal mutations in gen-
omic DNA from nine different Irbp-Cyclin D1, p18Ink4c
-/- pineal tumors (data not shown). Further, using pri-
mary cultures of pineal tumor cells, we found that both
gamma irradiation and treatment with etoposide resulted
in increased p53 phosphorylation and in p53-dependent
increases in p21Cip1 and 14-3-3 in Irbp-Cyclin D1,
p18Ink4c -/- but not Irbp-Cyclin D1, p53 -/- tumor cellsgnant senescent lesion. A) Representative pineal sections of Irbp-
. Arrowheads mark examples of Ki67-positive cells. B)
-Cyclin D1, p18Ink4c -/- pineal sections at 3.5 months. Asterisk denotes
neal lesion. Arrows indicate examples of cells with SAHF (positive for
d) in Irbp-Cyclin D1, Ink4c-/- pineal section at P49. Red arrows indicate
lotting for the indicated proteins in representative tumors from Irbp-
mpared to a P10 Irbp-Cyclin D1 pineal gland (D1). HA: HA tag of the
ins in tumor cells from Irbp-Cyclin D1, p53 -/- (D1p53nT) and Irbp-Cyclin
adiation or etoposide, as indicated. F) Western blotting for the
indicated ages and in tumor lysates as indicated.
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intact in Irbp-Cyclin D1, p18Ink4c -/- tumor cells. In
contrast, there was decreased p18Ink4c expression in
Irbp-Cyclin D1, p53-/- tumors, suggesting that p18Ink4c
may act as a tumor suppressor, even in a p53-null setting
[Figure 5D, 5F]. However, preliminary results show no
enhanced tumor susceptibility in Irbp-Cyclin D1, p53-/-,
p18Ink4c -/- (double knock-out) animals (data not
shown).
Cdk2 is induced in both p18Ink4c -/- and p53 -/-
tumors, and may be a suitable therapeutic target: Several
changes in Cdk2 expression suggested that it may repre-
sent a critical effector of Cyclin D1-driven tumorigenesis.
In the Irbp-Cyclin D1, and Irbp-Cyclin D1, p18Ink4c -/-
animals, Cdk2 was repressed as cells ceased to prolifer-
ate, and repression was markedly blunted in the Irbp-
Cyclin D1, p53 -/- pineal gland [Figure 5F, compare with
Figure 4D], in which neither cell cycle arrest nor senes-
cence was observed [see Figure 4A]. Repression of Cdk2
seemed specific because there was no repression of an-
other closely related cell cycle protein, Cdk1 [Additional
file 2: Figure S2D]. Lastly, Cdk2 increased in tumors pro-
gressing from the largely senescent, Irbp-Cyclin D1,
p18Ink4c -/- pineal gland [Figure 6A], and Cdk2 expres-
sion correlated with Ki67-positivity in emerging tumors
[Figure 6B]. Areas in the Irbp-Cyclin D1, p18Ink4c -/-
tumors that remained Ki67-negative displayed little Cdk2
[Figure 6B and 6C].
To address the role of Cdk2 repression as a possible
therapeutic target, we treated explanted Irbp-Cyclin D1,
p18Ink4c -/- and Irbp-Cyclin D1, p53 -/- pineal tumor cells
with the Cdk2-inhibitor CVT313, at a concentration of
5 μM, known to specifically inhibit Cdk2 [11,31]. CVT313
treatment decreased cell number (estimated by total cellular
area) in Irbp-Cyclin D1, p18Ink4c -/- and Irbp-Cyclin D1,
p53 -/- tumor cells in 8-well chamber slides [Figure 6D,
upper panel]. Furthermore, CVT313-treated cells showed
an increase in positive staining for SABG activity [Figure 6D,
lower panel, and Figure 6E]. Importantly, treatment of pre-
tumorigenic Irbp-Cyclin D1 pineal cells with CVT313 also
decreased the apparent cell number [Figure 6E], while treat-
ment of wild-type pineal cells did not seem to have a no-
ticeable effect, either on cellularity or SABG positivity
[Figure 6E].
We assessed whether Cdk2 inhibition by CVT313 was
primarily affecting cellular proliferation by BrdU incorpor-
ation assay. Indeed, we found that CVT313 treatment
decreased proliferation in oncogene-expressing and pre-
tumorigenic cells, but not in wild-type pineal cells
[Figure 7A, quantitation in Figure 7B]. There was no evi-
dence of any increase in apoptotic cells after CVT313 treat-
ment in either cell type, as measured by TUNEL staining
(negative data not shown).To investigate whether the effects on senescence in-
duction were specific to Cdk2 inhibition, we treated
explanted Irbp-Cyclin D1, p53-/- and Irbp-Cyclin D1,
p18Ink4c-/- cells with a specific Cdk4-inhibitor, NSC
625987 [32,33]. Inhibition of Cdk4 decreased prolifera-
tion (measured by BrdU incorporation), though to a
lesser extent than seen with Cdk2 inhibition [Figure 7C].
However, unlike Cdk2 inhibition, it did not result in any
detectable increase in SABG staining [Figure 7D]. This
demonstrates that Cdk2 inhibition was specifically rele-
vant to induction of senescence in Cyclin D1-expressing
pineal cells.
Discussion
Emerging evidence supports the concept that cellular
senescence represents a likely mechanism through which
oncogenic transformation is suppressed. Senescence has
been observed in pre-malignant lesions in mouse and in
man, but not in fully transformed counterparts of these
lesions (reviewed in [21,34]). Because of the time lag in
progression of premalignant lesions and the incomplete
penetrance, it has been assumed that accumulation of as
yet poorly-defined genetic or epigenetic changes likely
contribute to the emergence of a tumor from a premalig-
nant, apparently senescent lesion.
Our work provides new insight into cellular and mo-
lecular events that occur as oncogene-expressing cells ar-
rest, become senescent, and finally emerge or escape
from the senescent state as a malignant tumor. This is
the first in vivo description of temporal morphologic and
molecular events accompanying the evolution of an
oncogene-driven senescent state, showing a previously
unrecognized temporal sequence where cell cycle exit
preceded formation of heterochromatin foci by several
weeks.
Two tumor suppressor genes, p53 and p18Ink4c, played
distinct roles during this process. P53 activation occurred
concomitantly with an active DNA damage response, and
was essential to drive cell cycle exit, temporally associated
with Cdk2 repression and loss of Cdk2-dependent phos-
phorylation of the retinoblastoma protein Rb. Days later,
reversal of Cdk4-dependent phosphorylation of the Rb
protein correlated with the emergence of morphological
and biochemical changes of oncogene-induced senes-
cence. At that point, though, there was no evidence of
p53 pathway activation. This is the first direct in vivo evi-
dence for distinct temporal roles for these two tumor
suppressors in the senescence process.
The early and transient activation of the p53 pathway
suggested that p53 was integral for the initial cell cycle
exit but not directly involved in formation of SAHF.
Other models have also shown conflicting and context-
dependent evidence for the role of p53 in the formation
Figure 6 Cdk2 is a therapeutic target in tumors that have bypassed senescence. A) Western blotting for the indicated proteins in Irbp-Cyclin
D1, p18Ink4c -/- (D1p18null) pineal lysates at the indicated ages, Irbp-Cyclin D1, p18Ink4c -/- (D1p18null) tumors that are early (ET1, ET2) or well-
established (T3 – T7), and in Irbp-Cyclin D1, p53 -/- (p53T) tumor lysates, as indicated. B) Representative immunohistochemical staining for Cdk2
and Ki67, as indicated, in serial sections of Irbp-Cyclin D1, p18Ink4c -/- pineal glands (PG1 and PG2) that have an emerging tumor within a
senescent background. “T” denotes the emerging tumor; “PG” denotes the pineal gland background. C) Representative immunohistochemical
staining for Cdk2 and Ki67, as indicated, in serial sections of Irbp-Cyclin D1, p18Ink4c -/- tumors (T1 and T2), showing areas of low Ki67 and low
Cdk2 positivity (asterisks). D) Quantitation of cellular accumulation (upper panel) and SABG-positive proportion (lower panel) of Irbp-Cyclin D1,
p18Ink4c -/- and Irbp-Cyclin D1, p53 -/- tumor cells after treatment for 7 days with CVT313 or vehicle, as indicated. Asterisk denotes statistical
significance (p-value = 2.7 × 10-3, 9.8 × 10-4 respectively, for the upper panel; 6.4 × 10-4 and 6.3 × 10-4, respectively for the lower panel). E)
Representative SABG staining of wild-type (WT, upper panel), pretumorigenic Irbp-Cyclin D1 (D1, second panel), Irbp-Cyclin D1, p18Ink4c -/-
(D1p18n, 3rd panel) and Irbp-Cyclin D1, p53 -/- (D1p53n, lower panel) tumor cells in culture, treated for 7 days with CVT313 or vehicle, as indicated.
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and stable. Rb seemed to be important in both cell cycle
exit as well as formation of SAHF: compromise of the
Rb pathway through loss of p18Ink4c (the major known
function of which is inhibition of Cdk4/6 to indirectly
activate Rb [38-40]) led to a delay in initial cell cycle exit,and eventually to complete penetrance of tumor progres-
sion within the senescent-like lesion. Taken together,
these findings implicate Rb, rather than p53, as the key
protein needed to foster the emergence and maintenance
of SAHF, thought to be responsible for repression of
cell-cycle genes [3,35]. Involvement of Rb in the
Figure 7 Cdk2 inhibition in tumor cells leads to features of senescence. A) BrdU-incorporation and immunofluorescence staining (red), and
corresponding DAPI staining (blue), of cultured wild-type (WT), Irbp-Cyclin D1 (D1), and Irbp-Cyclin D1,p53-/- (D1p53-/-) pineal cells, as indicated,
after 7 days of treatment with CVT313 (CVT) or an equal volume of DMSO vehicle (Vh). B) Quantitative analysis of percent BrdU-positive cells in
wild-type (WT) and Irbp-Cyclin D1 (D1), and Irbp-Cyclin D1,p53-/- (D1p53-/-) pineal cells treated for 7 days with CVT313 (CVT) or vehicle (Vh). Asterisk
denotes statistical significance. C) Quantitative analysis of percent BrdU-positive cells in Irbp-Cyclin D1,p18Ink4c-/- tumor cells treated for 7 days
with CVT313 (CVT), NSC625987, or vehicle (Vh). Asterisk denotes statistical significance. Double asterisk is for statistically significant decrease in
comparison to both other conditions. D) Representative SABG staining of Irbp-Cyclin D1, p53 -/- (D1p53-/-) and Irbp-Cyclin D1, p18Ink4c -/-
(D1p18-/-) tumor cells in culture, treated for 7 days with CVT313, NSC625987, or vehicle, as indicated.
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human RB was shown to directly co-localize with SAHF
[35,36], and inactivation of the p16INK4a/RB pathway
impairs formation of RasG12V-induced SAHF in human
fibroblasts [35]. In our model, p53-driven cell cycle exit
correlated with hypo-phosphorylation of Rb at Cdk2-
dependent sites, while formation of SAHF correlated
with hypo-phosphorylation at Cdk4-dependent sites.
This suggests that hypo-phosphorylation of these specific
residues may be involved in SAHF formation. It will be
interesting to evaluate whether mutated forms of Rb that
cannot be phosphorylated at these particular Cdk4 sites
can more robustly foster the appearance of SAHF.
Our results suggest that p53 and p18Ink4c represent
separate tumor suppressor pathways in Cyclin D1-driven
pineoblastoma. While tumors progressed within 3-
4 months in p53 -/- animals, they appeared much later,
after 7-10 months in p18Ink4c -/- mice. Also, the p53
pathway was intact in p18Ink4c -/- tumors, further prov-
ing that the two pathways of tumor suppression are dis-
tinct. Tumor suppression required functional p53 andp18Ink4c, as neither was sufficient to prevent tumor pro-
gression alone. While the cell cycle exit after P10 was
clearly p53-dependent, absence of p18Ink4c delayed the
cell cycle exit but did not prevent it in the majority of
cells, which went on to express other markers of senes-
cence. However, few cells continued to proliferate, result-
ing in tumorigenesis. It thus appears that, while p53 loss
resulted in abrogation of cell cycle exit altogether, loss of
p18Ink4c decreased the threshold for bypass of the p53-
dependent cell cycle exit in a subset of cells.
In our model, p53-dependent cell cycle arrest was asso-
ciated with marked Cdk2 repression, while Cdk2 levels
were maintained in Irbp-Cyclin D1, p53 -/- cells which
never exited the cell cycle [see Figure 5F]. While a role
for Cdk2 repression in facilitating senescence has been
shown in an earlier report [11], ours is the first descrip-
tion of Cdk2 repression occurring in a temporal associ-
ation with p53-dependent cell cycle exit. This indicates
that Cdk2 repression might be a novel p53-dependent
mechanism to foster cell cycle exit, especially since no
similar changes were seen in the related cell cycle
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http://www.molecular-cancer.com/content/11/1/28regulator Cdk1. However, additional work will be needed
to investigate whether Cdk2 repression is a direct p53-
dependent effect, and whether it is sufficient to induce
cell cycle exit and induction of senescence. Moreover,
since Cdk2 and other Cdks are also regulated post-tran-
scriptionally by phosphorylation and by their binding to
CDK-inhibitors, future work should focus on elucidating
these molecular aspects for complete mechanistic under-
standing of the role of Cdk2 and other Cdks in inducing
senescence. Future studies utilizing the established
in vitro model, as well as genetically engineered mouse
models, should be able to specifically dissect the role of
Cdk2 in tumor progression, and upstream and down-
stream mechanisms leading to its repression and to cell
cycle exit.
Finally, although tumors arising in a p53 -/- setting
were molecularly different from those arising in a
p18Ink4c -/- setting, Cdk2 levels were high in both
(compared to senescent cells) and both cell types
responded to Cdk2 inhibition. While Cdk4 inhibition also
decreased cell proliferation, only Cdk2 inhibition resulted
in features of senescence in treated cells. These conclu-
sions are based on the published specificity of the inhibi-
tors used at the corresponding concentrations. Ideally, we
would have preferred to document inhibitor-induced pRb
specific phosphorylations and specific kinase activity in
each experiment, however the low number of primary
cells used in these experiments was prohibitive.
Keeping the above limitations in mind, these findings
provide a rationale for exploring the use of pharmaco-
logical Cdk inhibition, specifically Cdk2, to induce senes-
cence in tumor cells, irrespective of whether the p53
pathway is compromised. Such an approach to therapy
may be especially useful in tumors where the primary in-




Irbp-Cyclin D1 transgenic mice [41] were bred with p53
-/- (Jackson Laboratory, Maine), or p18Ink4c -/- mice
[42] and maintained in a mixed C57BL/6 × 129/Sv genetic
background. PCR for targeted alleles was used to verify
mouse genotypes as described [41,42]. Animals were
euthanized at defined time points or when obviously ill in
accordance with the American University of Beirut
(AUB) Institutional Animal Care and Use Committee
guidelines; all studies were approved by this committee.
Analyses of protein expression
Protein lysates were prepared from pineal tissue by
lysis in Universal Lysis Buffer. Electrophoresis was per-
formed using 8, 10, or 12% Tris-Chloride gels, trans-
ferred to polyvinylidene difluoride membranes (Bio-RadLaboratories, Hercules, CA), and detected using anti-
bodies to p21Cip1, Cdk4, Cdk2, Cdk1, Hsc70, phospho-
S790 Rb, total and phospho-specific p53 at Ser15/20
(Santa Cruz Biotechnology, Santa Cruz, CA); phospho-
S612 Rb (MBL International, Woburn, MA); p18Ink4c
(Zymed, San Francisco, CA); human Cyclin D1 (BD-
Pharmingen, San Diego, CA); hemagglutinin (HA) epi-
tope (Covance, Trenton, NJ); and 14-3-3 (Abcam,
Cambridge, UK).
For evaluation of p53 pathway, pineal tumors were
excised, dispersed, and plated onto permanox chamber
slides, and grown in culture in 10% FBS in DMEM for
72 hours, then treated with 6 Gy irradiation at 1 Gy/min,
or 10 μM Etoposide. Cells were collected 24 hours after
irradiation, or 6 hours after Etoposide treatment, and
protein extraction and western blotting was performed as
above.
Histological studies and Immunostaining
Brain tissue was fixed in 4% paraformaldehyde for
72 hours then embedded in paraffin. For mice older
than 10 days, skulls were peeled off before embedding.
For BrdU incorporation, 49 day-old mice were treated
with intraperitoneal injection of 50 mg/Kg of BrdU
(Sigma-Aldrich, St Louis, MO), every 2 hours × 5, then
sacrificed 2 hours later. 4-8 μm sections were cut from
paraffin-embedded tissues and deparaffinized. Antigen
retrieval was performed in a microwave at high power
for 5 minutes, followed by low power for 5 minutes x2
in citrate antigen retrieval buffer (pH 6.0). Slides were
incubated with anti-Ki67 (NovoCastra, Newcastle, UK),
anti-pH2AX (Cell Signaling Technology, Danvers, MA),
anti-Dec1, anti-DcR2, anti-MnSOD, anti-p15Ink4b, or
anti-Cdk2 antibodies(Santa Cruz Biotechnology), fol-
lowed by biotinylated secondary antibody; and detected
using streptavidin conjugated to horseradish peroxidase
and DAB substrate (DAKO, Carpinteria, CA). For im-
munofluorescence staining, anti-H3K9me3 (Upstate La-
boratories, Syracuse, NY), anti-4HNE (Alpha
Diagnostic, San Antonio, TX, USA), anti-BrdU, anti-
p21 (Santa Cruz Biotechnology), anti-phosphorylated
Chk1 at Ser345 (Cell Signaling Technology), anti-14-3-
3, and anti-8(OH)dG (Abcam, Cambridge, UK) anti-
bodies were detected with Cyanine 2, Cyanine 3, or
Alexafluor488 secondary antibodies. The number of
Ki67 positive cells, pH2AX positive cells, and BrdU-
positive cells was manually counted from 5-7 represen-
tative fields, at 200x magnification, and normalized to
total cell number. Digital photomicrographs were
obtained using a Zeiss 510 NLO multiphoton/ confocal
laser scanning microscope. Composite images were
constructed using Photoshop CS4 software (Adobe Sys-
tems, Mountain View, CA).
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Pineal cells were explanted at postnatal day 10 (P10);
tumors were explanted when clinically apparent (bulging
cranium). Cells were plated onto 8-well permanox cham-
ber slides (Nunc, Rochester, NY), and cultured in
DMEM with 10%FBS, 1% glutamine, and 1% Pen/Strep.
DCFDA Assay
To measure intracellular ROS in vitro, cells were treated
with a peroxide sensitive reagent CM-H2DCF-DA (CM-
H2DCF-DA; Molecular Probes, Eugene, OR) at 10 μM for
20 min at 37°C and observed under a fluorescence
microscope.
N-Acetyl Cysteine treatment
Explanted pineal cells were treated with N-Acetyl Cysteine
(Sigma Aldrich) at a concentration of 5 mM. Media was
renewed daily. Cells were treated for 10 days, and stained
for SABG as described [20]. For DDR pathway analysis, cells
were fixed and stained after 4 days.
CVT313 and NSC625987 treatment
Explanted cells were treated with CVT313 at 5 μM (Santa
Cruz Biotechnology), NSC625987 at 1 μM (Tocris
Bioscience, Ellisville, MO, USA), or DMSO vehicle; media
was renewed every 3 days. Cells were fixed and stained for
SABG after 7 days, and counterstained with eosin. For
quantification of proportion of cells positive for SABG, 10
random fields were selected, and digital photomicrographs
were analyzed using Adobe Photoshop CS4 software, by
color selection and area analysis. For quantification of cellu-
lar accumulation, all the area of the well was photographed
over 12 fields. Digital photomicrographs were analyzed
using Adobe Photoshop CS4 software, by area selection
tool. For BrdU incorporation assay, cells were treated with
BrdU at a concentration of 33 μM for 2 hours, fixed with
50%methanol/50%acetone solution for 2 minutes, then pro-
cessed as detailed above.Additional files
Additional file 1: Figure S1: A) High-magnification images of
senescence-associated heterochromatin foci (SAHF) marked by H3K9me3,
in Irbp-Cyclin D1 (D1) versus wild-type (WT) pineal cells at P49. B)
Senescence-associated beta galatosidase (SABG) staining of cultured
pineal cells explanted from wild-type (WT), Irbp-Cyclin D1 (D1), and Irbp-
Cyclin D1, p53 -/- (D1p53-/-) animals, as indicated. SABG staining was
done after 10 days of culture. C) Top panel: BrdU-incorporation and
immunofluorescence staining of wild-type (WT) and Irbp-Cyclin D1 (D1)
pineal cells, as indicated, after 10 days in culture. Bottom panel:
corresponding DAPI-stained nuclei. D) Right panels: Immunofluorescence
staining for 8(OH)dG and pH2AX, in wild-type (WT), Irbp-Cyclin D1 (D1),
and NAC-treated Irbp-Cyclin D1 explanted pineal cells, as indicated. Left
panels: corresponding DAPI staining of nuclei.
Additional file 2: Figure S2: A) Representative immunohistochemical
staining for Ki67 (left) and immunoflourescence for H3K9me3 (right) andcorresponding DAPI (middle) staining of Irbp-Cyclin D1, p18Ink4c-/- pineal
sections at the indicated ages. B) Immunostaining for Dec1 and DcR2, in
Irbp-Cyclin D1, p18Ink4c-/- pineal glands at the indicated ages. C) SABG
staining of cultured Irbp-Cyclin D1, p18Ink4c -/- pineal cells after 14 and 20
days in culture, as indicated. D) Western blotting for the indicated
proteins in pineal glands of the indicated genotypes, at the indicated
ages.
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